Grass Pollen Allergy - Pipeline Review, H2 2016

Date: August 31, 2016
Pages: 56
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G8C4BE872A3EN
Leaflet:

Download PDF Leaflet

Grass Pollen Allergy - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Grass Pollen Allergy - Pipeline Review, H2 2016’, provides an overview of the Grass Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Grass Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy
  • The report reviews pipeline therapeutics for Grass Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Grass Pollen Allergy therapeutics and enlists all their major and minor projects
  • The report assesses Grass Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Grass Pollen Allergy
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Grass Pollen Allergy Overview
Therapeutics Development
Pipeline Products for Grass Pollen Allergy - Overview
Grass Pollen Allergy - Therapeutics under Development by Companies
Grass Pollen Allergy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Grass Pollen Allergy - Products under Development by Companies
Grass Pollen Allergy - Companies Involved in Therapeutics Development
ALK-Abello A/S
Allergy Therapeutics Plc
Biomay AG
Circassia Pharmaceuticals Plc
HAL Allergy BV
Roxall Medizin GmbH
Shionogi & Co., Ltd.
Grass Pollen Allergy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
asapiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-32 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clustoid wiesenlieschgras - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pollinex Quattro Grass - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Grass Pollen Allergy - Dormant Projects
Grass Pollen Allergy - Product Development Milestones
Featured News & Press Releases
Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204
Jun 13, 2016: New Data From GAP Landmark Trial Confirm GRAZAX Prevents Asthma Symptoms in Children
May 25, 2016: Circassia Initiates Grass Allergy Immunotherapy Registration Study
Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL
Jan 28, 2016: Biomay initiates new phase II clinical trial with grass pollen allergy vaccine BM32
Jan 14, 2016: ALK announces top-line results from the five-year landmark GRAZAX Asthma Prevention trial in children
Jun 03, 2015: Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference.
Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32
Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK
Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study
Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)
Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32
Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK
Dec 10, 2013: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the grass sublingual AIT tablet
Nov 09, 2013: Merck’s Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Grass Pollen Allergy, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Products under Development by Companies, H2 2016
Grass Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2016
Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H2 2016
Grass Pollen Allergy - Pipeline by Biomay AG, H2 2016
Grass Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
Grass Pollen Allergy - Pipeline by HAL Allergy BV, H2 2016
Grass Pollen Allergy - Pipeline by Roxall Medizin GmbH, H2 2016
Grass Pollen Allergy - Pipeline by Shionogi & Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Grass Pollen Allergy - Dormant Projects, H2 2016

LIST OF FIGURES

Number of Products under Development for Grass Pollen Allergy, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

ALK-Abello A/S
Allergy Therapeutics Plc
Biomay AG
Circassia Pharmaceuticals Plc
HAL Allergy BV
Roxall Medizin GmbH
Shionogi & Co., Ltd.
Skip to top


Birch Pollen Allergy - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 49 pages

Ask Your Question

Grass Pollen Allergy - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: